All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2020-06-23T13:18:00.000Z

What was new in MCL at #ASCO20 and EHA 2020?

Featured
Jun 23, 2020
Share:

Bookmark this article

The Lymphoma Hub was happy to speak to Simon Rule, Derriford Hospital, Plymouth Hospitals NHS Trust, Plymouth, UK. We asked, What was new in mantle cell lymphoma at this year's American Society of Clinical Oncology (ASCO) and European Hematology Association (EHA) virtual meetings?

Here, Simon Rule provides a comprehensive overview of the highlights in mantle cell lymphoma presented at the two meetings, focusing mainly on EHA 2020.

What was new in MCL at ASCO and EHA 2020?

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Your opinion matters

Given there are no currently approved treatment options for patients with Waldenstrom’s macroglobulinemia in the third-line setting, what major response rate threshold would make you consider adopting a new radiotherapy option in this setting?
1 vote - 9 hours left ...

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox